Cadila Healthcare soars on USFDA clearance for Moraiya facility
Cadila Healthcare has soared 5% to Rs 837 after the company said it has received a letter from USFDA, conveying that the facilities at Moraiya are acceptable.
“With this, the warning letter issued by them earlier is resolved," Cadila Healthcare said in a filing. According to analysts, this move will provide a strong impetus to the stock as Cadila has 17 injectable filings from this facility.
“The US business is expected to grow by 20% plus in FY2013 and FY2014 on the back of 10-15 new launches every year, “ Angel Broking said in its report.
The stock opened at Rs 805 and touched high of Rs 838 on the National Stock Exchange. A combined 96,574 shares have already changed hands on the counter in morning trades, as against an average of less than 100,000 shares that were traded daily in past two weeks.
Read Other Stories